Previous 10 | Next 10 |
Shares of Adaptimmune Therapeutics (NASDAQ: ADAP) , a small-cap cancer immunotherapy company, slid by a hefty 21% during the first six months of 2021, according to data from S&P Global Market Intelligence . By contrast, the biotech's shares were among the hottest in the enti...
Shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP) traded at a new 52-week low today of $3.63. So far today approximately 263,000 shares have been exchanged, as compared to an average 30-day volume of 799,000 shares. Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical co...
Baker Brothers’ 13F portfolio value decreased from $26.54B to $23.07B this quarter. The large stake in Alexion Pharmaceuticals was decreased during the quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~57% of the portfol...
Shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP) traded at a new 52-week low today of $3.68. Approximately 263,000 shares have changed hands today, as compared to an average 30-day volume of 1.1 million shares. There is potential upside of 5.5% for shares of Adaptimmune Therapeutics ...
Dogecoin (CRYPTO: DOGE) , in many ways, is at the epicenter of the cryptocurrency craze. Its price appreciated by a staggering 12,000% during just the first five months of 2021. The probability that this star of the cryptocurrency world will keep churning higher, however, appears to...
I covered Adaptimmune in December. This article covers all that has changed since then. A BLA filing next year could be a major catalyst. For further details see: Adaptimmune Therapeutics: Still The TCR Leader, And With Major Upcoming Catalysts
ASCO is a very important cancer clinical research meeting. We identified 70 smid-cap cancer companies presenting updated clinical data at ASCO21. 13 companies' value increased by over 10% with ASCO21 info release thus far. PDSB is an early ASCO21 mover, with its HPV vaccine ca...
Seeing a bigger upside from overweight-rated stocks in its coverage, Barclays has initiated Adaptimmune Therapeutics ([[ADAP]] -2.0%) with an underweight recommendation.The price target of $4.00 per share indicates a downside of ~20.8% to the previous close. After two consecutive days of gain...
Adaptimmune Therapeutics (NASDAQ: ADAP) , a biotech company active in the hot immunotherapy segment, was a high-temperature stock on Thursday. Following the release of detailed phase 2 clinical trial results for a promising cancer treatment, the company's shares rose by nearly 4.5% ...
Adaptimmune Therapeutics shares rise ([[ADAP]] +4.9%) as the company talked up initial data from its mid-stage afamitresgene autoleucel cancer trial ahead of its presentation at the upcoming American Society of Clinical Oncology ((ASCO)) congress.At the time of data cut-off, 37 patients had r...
News, Short Squeeze, Breakout and More Instantly...
Adaptimmune Therapeutics plc Company Name:
ADAP Stock Symbol:
NASDAQ Market:
Adaptimmune Therapeutics plc Website:
Approved for advanced MAGE-A4+synovial sarcoma in adults with certain HLA types who have received prior chemotherapy TECELRA is the first new treatment option for people with synovial sarcoma in more than a decade Adaptimmune to hold webcast at https://www.gowebcasti...
2024-07-30 07:30:03 ET H.C. Wainwright analyst issues BUY recommendation for ADAP on July 30, 2024 06:07AM ET. ADAP was trading at $1.37 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 4 - Buy, 1 - Hold, ...
2024-07-30 07:00:10 ET Arthur He from H.C. Wainwright issued a price target of $4.00 for ADAP on 2024-07-30 06:07:00. The adjusted price target was set to $4.00. At the time of the announcement, ADAP was trading at $1.37. The overall price target consensus is at $2.54 wi...